|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 31/7115 | (2006.01) |
| C07K 16/244 | (2013.01) | ||
| A61K 39/39 | (2006.01) | ||
| A61K 45/06 | (2013.01) | ||
| A61K 45/06 | (2006.01) | ||
| C07K 16/2818 | (2013.01) | ||
| A61K 9/00 | (2006.01) | ||
| C07K2317/76 | (2013.01) | ||
| A61N 5/00 | (2006.01) | ||
| A61K 31/7115 | (2013.01) | ||
| C07K 14/435 | (2006.01) | ||
| A61P 35/00 | (2018.01) | ||
| A61P 35/00 | (2006.01) | ||
| C07K 14/435 | (2013.01) | ||
| A61K2039/505 | (2013.01) | ||
| A61K2039/55561 | (2013.01) |
| (11) | Number of the document | 3302501 |
| (13) | Kind of document | T |
| (96) | European patent application number | 16804054.1 |
| Date of filing the European patent application | 2016-05-26 | |
| (97) | Date of publication of the European application | 2018-04-11 |
| (45) | Date of publication and mention of the grant of the patent | 2021-09-22 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2016/034275 |
| Date | 2016-05-26 |
| (87) | Number | WO 2016/196173 |
| Date | 2016-12-08 |
| (30) | Number | Date | Country code |
| 201562168449 P | 2015-05-29 | US | |
| 201562169309 P | 2015-06-01 | US |
| (72) |
YU, Ying , US
DENKER, Andrew Evan , US
SADEKOVA, Svetlana , US
PHAN, Uyen Truong , US
KASTELEIN, Robert A. , US
KAUFMAN, David Ross , US
COFFMAN, Robert L. , US
GUIDUCCI, Cristiana , US
JANSSEN, Robert S. , US
|
| (73) |
Merck Sharp & Dohme Corp. ,
126 East Lincoln Avenue, Rahway, NJ 07065-0907,
US
Surefire Medical, Inc. , d/b/a TriSalus Life Sciences 6272 West 91st Avenue, Westminster, CO 80031, US |
| (54) | COMBINATION OF A PD-1 ANTAGONIST AND CPG-C TYPE OLIGONUCLEOTIDE FOR TREATING CANCER |
| COMBINATION OF A PD-1 ANTAGONIST AND CPG-C TYPE OLIGONUCLEOTIDE FOR TREATING CANCER |